Want to see SE:MAGLE full AI Analyst Report?
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr0.43 - kr23.60
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.06K
Market Cap
kr14.83M
Enterprise Valuekr363.38
Total Cash (Recent Filing)kr0.00
Total Debt (Recent Filing)kr356.15M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.76
Shares Outstanding30,263,191
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr285.10M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustainably high gross margins are a structural advantage in pharmaceutical manufacturing: they provide a buffer against revenue volatility, allow room to cover fixed costs, and improve the odds of returning to profitability if top-line recovery and cost control follow. This margin resilience supports longer-term cash generation once volumes normalize.
Moderate Leverage (debt Below Equity)Having debt below equity and moderate leverage provides financial flexibility during a turnaround. It lowers refinancing and distress risk, preserving capacity to raise capital or secure credit lines to fund operations or bridge cash shortfalls without being immediately overburdened by interest expense.
Diversified Pharma Development And Manufacturing ModelA combined product-development and contract-manufacturing business model diversifies revenue sources: service contracts can provide recurring, fee-based income while internal pipeline upside exists. Structural industry outsourcing trends favor specialist CMOs, which supports sustainable demand for manufacturing services over time.
Bears Say
Persistent Negative Cash FlowMulti-year negative operating and free cash flow indicates structural cash burn rather than a one-off timing issue. This erodes liquidity, forces reliance on external financing or asset dispositions, restricts reinvestment in R&D and capacity, and increases the risk that operations cannot be sustained without material strategic changes.
Revenue Decline And Swing To Operating LossesA reversal from multi-year revenue growth to a sharp TTM decline coupled with a move from profits to sizable operating losses signals weakening demand or structural margin pressure. This undermines scale economics, complicates recovery, and means management must deliver durable revenue or cost fixes to restore profitable operations.
Erosion Of Equity And Weakened Balance SheetSignificant equity erosion from consecutive losses reduces the capital base and financial resilience. A weakened equity position limits ability to absorb further losses, raises the likelihood of dilutive financing, constrains M&A or investment options, and heightens vulnerability to adverse shocks or covenant triggers.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr0.43 and its highest was kr23.60 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr14.83M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Nov 02, 2026 which is in 78 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Aug 12, 2026. The company reported -kr0.821 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of N/A. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 30,263,191 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -kr0.821 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Technical Analysis
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Corline Biomedical AB
―